Archives of Science
Open Access

Selective internal radiation therapy; Neuro endocrine tumors; Peptide receptor radionuclide therapy; Single-photon emission computed tomography

Introduction

High-grade neuroendocrine tumors (NETs) represent a complex and aggressive form of cancer, characterized by rapid growth and a propensity for metastasis [1]. Metastatic spread significantly affects prognosis and treatment decisions in patients with high-grade NETs. Understanding the specific metastatic niches within the body is crucial for effective management and targeted therapies. In this article, we explore the latest advancements in the identification of metastatic niches in patients with high-grade neuroendocrine tumors, shedding light on their clinical significance and potential implications for personalized treatment strategies [2]. Metastasis is a multistep process involving the dissemination of tumor cells from the primary site to distant organs or tissues. High-grade NETs can metastasize to various locations, including the liver, lungs, bones, and lymph nodes. Identifying these metastatic niches is essential for accurate staging and treatment planning [3]. Traditional imaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI) , have limitations in detecting small metastases or differentiating them from benign lesions. Therefore, innovative approaches are being explored to improve the identification and characterization of metastatic niches [4].

Discussion

Nuclear medicine sequence imaging, including positron emission tomography (PET) and single-photon emission computed tomography (SPECT), has emerged as a valuable tool in the identification of metastatic niches in high-grade NETs [5]. These techniques utilize radiolabelled molecular probes that specifically target neuroendocrine tumor cells, facilitating their visualization and precise localization within the body. In recent years, the development of triple-positive radiolabelled molecular probes has significantly improved the sensitivity and accuracy of nuclear medicine sequence imaging for identifying metastatic niches [6].

Triple-positive radiolabelled molecular probes are designed to target multiple biomarkers expressed on high-grade NET cells. By combining different molecular targets, these probes enhance specificity and reduce false-positive results. Commonly targeted biomarkers include somatostatin receptors (SSTR), glucose transporters (GLUT), and receptors for gastrin-releasing peptide (GRP) [7]. The radiolabelled probes bind to these receptors, allowing for the detection and visualization of neuroendocrine tumor cells even in small metastatic lesions. Accurate identification of metastatic niches in high-grade NETs has significant clinical implications [8]. It enables precise staging, aids in treatment decision-making, and assists in monitoring disease progression and response to therapy. Metastatic lesions identified through nuclear medicine sequence imaging can be targeted with sitespecific therapies, such as peptide receptor radionuclide therapy (PRRT) or selective internal radiation therapy (SIRT) [9]. These approaches deliver high-dose radiation directly to the metastatic lesions, sparing healthy tissue and improving treatment outcomes [10].

Conclusion

The identification of metastatic niches in patients with high-grade neuroendocrine tumors is crucial for optimal disease management. Nuclear medicine sequence imaging, particularly with triple-positive radiolabelled molecular probes, has emerged as a promising tool for detecting and characterizing metastatic lesions with high sensitivity and specificity. By accurately identifying metastatic niches, clinicians can tailor treatment strategies, offering targeted therapies and improving patient outcomes. Continued research and technological advancements in this field hold the promise of further enhancing our understanding and management of high-grade Nets. Several molecular biomarkers used for CSCs identification showed signatures variation in a single tumors type, as well as common/overlapped signatures between different types of solid tumors. Also, it is common to perform multiple biopsies because of evolving differentiation grades in primary and metastatic tumour sites, especially in G3 NETs and NECs of the digestive tract. The hypothesis of a dynamic transition of cell states and tumour evolution differs from the concept of heterogeneity in a tumour sample biopsy.

1. Tiwari PN, Kulmi GS (2004) Performance of Chandrasur (Lepidiumsativum) under different levels of nitrogen and phosphorus. J Med Aromatic Plant Sci 26: 479-481.

Google Scholar

2. Avachat AM, Dash RR, Shrotriya SN (2011) Recent investigation of plant based gums, mucilages and resins in novel drug delivery system. IJPR 45: 86-99.

Google Scholar

3. Basu SK (2006) Seed production technology for fenugreek (Trigonellafoenum- graecum L.) in the Canadian. Master of Science Thesis. Depart Biological Sci Uni of Lethbridge Alberta Canada 202-269.

Google Scholar

4. Huang H, Zhang S (2006) Flaxseed nutrient composition and application in food industry. Food Res Dev 27: 147-149.

Google Scholar

5. Morris DH (2003) Flax: A Health and Nutrition Primer. 3rd ed Flax Council of Canada Winnipeg MB Canada 11-33.

Google Scholar

6. Shim Y, Y GUI, B Arnison PG, Wang Y, Reaney MJT (2014) Flaxseed (Linumusitatissimum L.) bioactivecompounds and peptide nomenclature: A review. Trends Food Sci Technol 38: 5-20.

Google Scholar

7. Dwek R (1996) Glycobiology, “Towards understanding the function of sugars”. Chemical Review 96: 683- 720.

Indexed at, Google Scholar, Crossref

8. Ma F Wang, R Li, X Kang, W Bell AW (2020) “ Physical properties of mucilage polysaccharides from dioscoreaOppositaThunb”. Food Chem 311.

Google Scholar

9. Amin El S , Poleologu (1973) “Phytochemical and Biological Studies of Some Polysaccharides Isolated From Aloe, Tamarindus, Opuntia, and Citrus”. Res 27 (2): 447-50.

Google Scholar

10. Whistler RL (1965) "Methods in carbohydrate chemistry" Academic press New York London 5: 18-52.

Google Scholar